Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HMOX1 | P09601 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL410844 | 0.98 | TSHR (0.49) | TSHRMAPK1SMN1; SMN2L3MBTL1HMOX1 | |
| SCHEMBL10850007 | 0.92 | CYP11B1 (0.51) | TSHRMAPK1SMN1; SMN2L3MBTL1HMOX1 | |
| Hydrochloric Acid SCHEMBL9996055 | 0.90 | CYP11B1 (0.50) | HMOX1CYP11B1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL12045394 | 0.89 | LTA4H (0.51) | TSHRMAPK1SMN1; SMN2L3MBTL1HMOX1 | |
| SCHEMBL10853713 | 0.88 | CYP11B1 (0.51) | TSHRMAPK1SMN1; SMN2L3MBTL1HMOX1 | |
| Hydrochloric Acid SCHEMBL9996120 | 0.88 | KMT2A (0.52) | TSHRMAPK1SMN1; SMN2L3MBTL1HMOX1 | |
| SCHEMBL10850378 | 0.86 | CYP11B1 (0.49) | CYP11B1CYP11B2TBXAS1CYP19A1CYP1A2 | |
| SCHEMBL12045386 | 0.85 | HMOX1 (0.61) | MAPK1HMOX1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL11241264 | 0.85 | CYP11B1 (0.49) | HMOX1CYP11B1CYP11B2TBXAS1CYP19A1 | |
| SCHEMBL12045382 | 0.85 | CYP2A6 (0.50) | HMOX1CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | TSHR 2047/4885MAPK1 2234/4885SMN1; SMN2 213/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TSHR 3944/4885MAPK1 2284/4885SMN1; SMN2 95/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TSHR 3944/4885MAPK1 2284/4885SMN1; SMN2 95/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TSHR 4163/4885MAPK1 2159/4885SMN1; SMN2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.